Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Fusako Miyamoto"'
Publikováno v:
Antiviral Chemistry and Chemotherapy. 24:77-82
Background Direct comparison of enzymatic and original blue cell-counting detections with the multinuclear activation of an indicator (MAGI) cells, so far, remains to be performed in parallel. Although inhibitors for reverse transcription solely inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44561056e6bf21c242d9cec06450b21d
https://doi.org/10.1177/2040206615614164
https://doi.org/10.1177/2040206615614164
Autor:
Fusako Miyamoto, Takeshi Naito, Hua Qian, Kumi Kawaji, Toshio Hattori, Eiichi Kodama, Nobutaka Fujii, Shinya Oishi, Kazumi Kajiwara, Kentaro Watanabe, Masao Matsuoka, Xiaoguang Li
Publikováno v:
Biochemical and Biophysical Research Communications. 424:257-261
The lack of small animal models for the evaluation of anti-human immunodeficiency virus type 1 (HIV-1) agents hampers drug development. Here, we describe the establishment of a simple and rapid evaluation system in a rat model without animal infectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771001702d39028e0157826870dd95a0
https://doi.org/10.1016/j.bbrc.2012.06.097
https://doi.org/10.1016/j.bbrc.2012.06.097
Autor:
Kentaro Watanabe, Kazuya Shimura, Yasuko Sakagami, Mitsuo Kaku, Fusako Miyamoto, Kazuki Shimane, Nobutaka Fujii, Stefan G. Sarafianos, Shinya Oishi, Kumi Kawaji, Eiichi Kodama, Masao Matsuoka
Publikováno v:
Antimicrobial agents and chemotherapy. 57(8)
T-20EK is a novel fusion inhibitor designed to have enhanced α-helicity over T-20 (enfuvirtide) through engineered electrostatic interactions between glutamic acid (E) and lysine (K) substitutions. T-20EK efficiently suppresses wild-type and T-20-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80778b673ee5d5eed18d6fb48c480640
https://pubmed.ncbi.nlm.nih.gov/23689710
https://pubmed.ncbi.nlm.nih.gov/23689710
Autor:
Fusako Miyamoto, Eiichi Kodama
Publikováno v:
Current pharmaceutical design. 19(10)
Human immunodeficiency virus type 1 (HIV-1) primarily infects and then destroys CD4-positive lymphocytes, leading to the acquired immunodeficiency syndrome (AIDS). Over 20 drugs, most small and orally bioavailable, have been approved, and include rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5928ab24a7a618508ea3510e7ed16651
https://pubmed.ncbi.nlm.nih.gov/23092276
https://pubmed.ncbi.nlm.nih.gov/23092276
Autor:
Keisuke Yusa, Eiichi N. Kodama, Shinji Harada, Shigeyoshi Harada, Fusako Miyamoto, Yosuke Maeda, Kazuhisa Yoshimura, Yuzhe Yuan
Publikováno v:
Journal of AIDS & Clinical Research.
Viral entry is one of the most important targets for the efficient treatment of Human immunodeficiency virus type 1 (HIV-1)-infected patients. The entry process consists of multiple molecular steps: attachment of viral gp120 to CD4, interaction of gp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09d2c7c42e0e9fc09dc87b3aa4a5bcc2
https://doi.org/10.4172/2155-6113.s2-004
https://doi.org/10.4172/2155-6113.s2-004
Autor:
Eiichi Kodama, Fusako Miyamoto
Publikováno v:
Antiviral chemistrychemotherapy. 22(4)
The development of over 20 antiretroviral drugs has led to efficient and successful suppression of HIV-1 replication. In addition to common viral targets, such as reverse transcriptase and protease, new targets have been recently exploited, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f96c7e0392c2461586d604f198fb9b19
https://pubmed.ncbi.nlm.nih.gov/22182762
https://pubmed.ncbi.nlm.nih.gov/22182762